![[ REPLACE ME ]](http://www.gwfowler.org/theme/cornflower/images/logo.jpg){kind=logo}
Marilin Schneider
 |
Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, ketoconazole and any developments following regulatory approval, among other uncertainties. Kwo P, Lawitz E, McCone J, et al. Overall, 77 percent of the 595 patients in the study were enrolled pharmacist claritin in the United States. In a study with weight-based ribavirin, there was a higher rate of anemia among patients in the weight-based ketoconazole dosing group (29%) compared to the flat-dosing group (19%). SCHERING-PLOUGH DISCLOSURE NOTICE. Ribavirin causes hemolytic anemia. Contraindications PEGINTRON is contraindicated in patients with hypersensitivity to PEGINTRON or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in cirrhotic CHC patients before ketoconazole ofloxacin hair or during treatment. Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary pharmacist disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots. And international sites. About Schering-Plough Schering-Plough is an innovation-driven, science-centered global health care company. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe. Safety data from the study sho that the most com adverse events reported in the boceprevir arms were fatigue, anemia, nausea and headache. This approach may minimize atenolol and chlorthalidone omeprazole plan-b baldness medicine the period of time when there is a "functional monotherapy" with a direct antiviral, potentially reducing the likelihood for the development of resistance. In addition, SVR rates are not yet available and consequently results are not being reported for the boceprevir arm with low-dose REBETOL (n 59) compared to contemporaneous control (n 16) as described above. Patients plavix with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. The most com adverse events associated with PEGINTRON were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. In many, but not all cases, these disorders resolve after stopping PEGINTRON and/or INTRON A therapy. "The high response rates seen with boceprevir in this study are very exciting, especially given that genotype 1 is the most com and hardest to treat form plavix of hepatitis C," said Luigi Kwo, M.D., associate professor of medicine and medical director, liver transplantation, Department of Medicine, Division of Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, and lead investigator of the study. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. African-Americans represent 16 percent of the patients names of sleeping pills enrolled and 7 percent of patients in the study are cirrhotic. Update on Boceprevir Phase III Studies Schering-Plough is conducting two large ongoing pivotal Phase III studies of boceprevir in patients chronically infected actoplus met with HCV genotype 1. Depression was most com at 29%. 59th American names of sleeping pills Association for the Study of Liver Diseases (AASLD) Annual Meeting; Oct. The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health generic singulair products. The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23% in the INTRON A/REBETOL group and 31-34% in the PEGINTRON/REBETOL groups. Avoid Pregnancy REBETOL therapy should not be started until a report of a negative pregnancy test has been obtained immediately prior to planned initiation of therapy. Per protocol, if a patient does not have a 24-week post-treatment assessment, metformin and rosiglitazone the patient's 12-week post-treatment assessment will be utilized. Dose modifications due to adverse events occurred more frequently in the weight-based dosing group (29%) compared to the flat-dosing (23%) group. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its remeron colleagues around the world. Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. Injection site pain was reported in 2% of patients receiving PEGINTRON. 4 weeks of PEGINTRON (1.5 mcg/kg once weekly) generic hyzaar and REBETOL (800-1400 mg daily based on patient weight) therapy follo by the addition of boceprevir to the combination for 24 or 44 weeks (totaling 28 or 48 weeks of treatment), boceprevir in combination with PEGINTRON and REBETOL at the doses described above for 28 or 48 weeks, and, in Part II of generic cymbalta the study, boceprevir in combination with PEGINTRON and low-dose REBETOL (400-1000 mg daily based on patient weight) for 48 weeks, compared to a control of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) alone for 48 weeks (an approved treatment regimen). Psychiatric adverse events, which include insomnia, were com (57%) with PEGINTRON but similar to INTRON A (58%). About Hepatitis C Hepatitis C generic xenical is a serious and potentially life-threatening disease. In addition, fewer patients in the lead-in arms discontinued treatment due to viral breakthrough. This is an ongoing study and SVR 24 rates are not yet available for patients in the 48-week boceprevir arms or the 48-week control arm of pharmacist the study. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON. INTRON A (Interferon alfa-2b, recombinant) for Injection is contraindicated in patients with hypersensitivity to INTRON A or any component of the product, autoimmune hepatitis, and decompensated liver disease. Labeling for PEGINTRON and REBETOL Alpha interferons, including PEGINTRON and INTRON(R) A, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, sumatriptan and infectious disorders. PEGINTRON or INTRON A in combination with REBETOL therapy is additionally contraindicated in patients with hypersensitivity to ribavirin or any other component of the product, women who are pregnant, men whose female partners are pregnant, patients with hemoglobinopathies (e.g., thalassemia generic singulair major, sickle-cell anemia), and patients with creatinine clearance less than 50 mL/min. The majority of these cases were mild and responded to dose reductions. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. A Ribavirin Pregnancy Registry sumatriptan has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment, and for 6 months following cessation of treatment. Additional Safety Information Relapse of drug addiction/overdose has occurred in patients on PEGINTRON therapy. The information in this includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's clinical development plans and the potential for boceprevir. The study generic xenical in treatment-naive patients is known as HCV SPRINT-2 and the study in patients who failed prior treatment is known as HCV RESPOND-2. Ribavirin may cause birth defects and/or death of the unborn child. Consalvo, 1-908-298-7409, office, or 1-908-295-0928, mobile, or Investors, Stella Corey, 1-908-298-7436, cilostazol office,or Joe Romanelli, 1-908-298-7436, office all of Schering-Plough Web Site. The company is based in Kenilworth, N.J., and its Web site is /. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214. One study is in treatment-naive patients and the other in patients who failed prior generic cymbalta treatment (relapsers and nonresponders). Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON. Dental and periodontal disorders have been reported in patients receiving PEGINTRON or INTRON A in combination with REBETOL therapy. SAN Jason, / - / -- Schering-Plough Corporation today reported that a planned interim analysis of a Phase II study sho that boceprevir, its investigational oral hepatitis C protease inhibitor, in combination with peginterferon and ribavirin markedly increased sustained virologic response (SVR) rates with 28 weeks of therapy and nearly doubled SVR with 48 weeks of therapy compared to current standard of care, peginterferon and ribavirin (control group) for 48 weeks. SVR 12 is defined as undetectable HCV-RNA in plasma at 12 weeks after the end of treatment. Patients should be monitored closely with periodic clinical and laboratory evaluations. 31- , San Clayborne, CA, USA; Poster No. The HCV SPRINT-1 study was conducted at sites across the United States, Canada and Europe. Serious adverse events were similar between the two groups (12%), and discontinuations for adverse events (15% in weight-based dosing and 14% in flat dosing) were also similar. Dose reductions due to adverse reactions occurred in 42% of patients receiving PEGINTRON (1.5 mcg/kg)/REBETOL and in 34% of those receiving INTRON A/REBETOL. The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen. Patients should use at least two effective forms of contraception and have monthly pregnancy tests during therapy and for 6 months after completion of therapy. In the PEGINTRON/REBETOL combination trial, the incidence of serious adverse events was 17% in the PEGINTRON/REBETOL groups compared to 14% in the INTRON A/ REBETOL group. Important Safety Information Regarding U.S. In addition, the patient's immune system will have been activated and primed by PEGINTRON at the time that boceprevir is added to the regimen. Forward-looking statements relate to expectations or forecasts of future events. For more information about these ongoing Phase III studies, please visit /, search term boceprevir. It is the most com blood-borne infection in America and Europe, and the most com form of liver disease, affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. Prescribing information and the Medication Guide for PEGINTRON at /. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A, "Risk Factors" in the company's third quarter 2008 10-Q. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients during therapy and 6 months post-treatment. Treatment discontinuations due to adverse events were between 9 and 19 percent for patients in the boceprevir arms, compared to 8 percent for the control arm. Treatment discontinuations for boceprevir patients due to viral breakthrough were fewer in the 28- and 48-week lead-in arms (4 and 5 percent, respectively) compared to the no lead-in arms (7 and 11 percent, respectively). "Boceprevir was well tolerated by patients in this study, and the use of the 4-week lead-in prior to the addition of boceprevir appears to reduce the incidence of viral breakthrough regardless of treatment duration and may improve SVR over a 48-week treatment period." The rationale for this novel lead-in treatment regimen is based on the fact that both PEGINTRON and REBETOL reach steady-state concentrations by week 4, so patients have the protease inhibitor added at a time when the backbone drug levels have been optimized. About the HCV SPRINT-1 Study In this Phase II study, known as HCV SPRINT-1 (HCV Serine Protease Inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated in three treatment regimens. If psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended that treatment with PEGINTRON and/or INTRON A be discontinued, and the patient be carefully follo with psychiatric intervention, as appropriate. About PEGINTRON In the United States, PEGINTRON is indicated for use alone or with ribavirin for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and who are at least 18 years of age. Intention-To-Treat (ITT) analysis includes any patient who has taken at least one dose of any study drug. / A service of YellowBrix, Inc.. Interim Results from the HCV SPRINT-1 Study. SVR, the protocol specified primary efficacy endpoint, is defined as achievement of undetectable HCV-RNA at 24 weeks after the end of treatment. Schering-Plough does not assume the obligation to update any forward-looking statement. Incidence of Adverse Events There are no new adverse events specific to PEGINTRON as compared to INTRON A; however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. These results compared to a 38 percent SVR rate (SVR 12) for patients in the control group receiving 48-weeks of PEGINTRON and REBETOL alone (ITT).(2-4) Importantly, predictability of attaining SVR 12 or 24 based on rapid virologic response (RVR) was greater for boceprevir patients in the lead-in arms compared to the no lead-in arms. Please see important full U.S. No increase in skin adverse events (rash or pruritus) was observed in the boceprevir arms beyond what was seen in the PEGINTRON and REBETOL control arm. The two randomized, double-blind, placebo-controlled studies evaluate the efficacy of boceprevir in combination with PEGINTRON and REBETOL compared to standard of care with PEGINTRON and REBETOL alone. The two studies are expected to enroll a total of more than 1,400 patients at U.S. RVR is defined as undetectable virus (HCV-RNA) in plasma on or before week 4 of boceprevir treatment. Schering-Plough Corporation CONTACT. The protocol specified primary efficacy endpoint of the HCV SPRINT-1 study is SVR as defined above. Boceprevir Plus Peginterferon alfa-2b/Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients. Aggressive behavior sometimes directed towards others has occurred in patients with and without a previous psychiatric disorder during PEGINTRON and/or INTRON A treatment and follow-up. Cases of encephalopathy have been observed in some patients, usually elderly, treated with higher doses of PEGINTRON and/or INTRON A. If patients develop psychiatric problems, including clinical depression, it is recommended that patients be carefully monitored during treatment and in the 6-month follow-up period. These results from the HCV SPRINT-1 study in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 were presented at the 59th American Association for the Study of Liver Diseases (AASLD) Annual Meeting.(1) In a 48-week boceprevir regimen, the SVR rate was 74 percent at 12 weeks after the end of treatment (SVR 12) in patients who received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) prior to the addition of boceprevir (800 mg TID) (P/R lead-in). Application site disorders were com (47%), but all were mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). In a 28-week boceprevir regimen, the SVR rate was 56 percent at 24 weeks after the end of treatment (SVR 24) in patients who received the P/R lead-in. The primary endpoint of the study is SVR after 24 weeks of follow up (SVR 24). Sustained Virologic Response (ITT) Treatment Arm All patients No P/R Lead-in 28 Weeks 55% (59/107) P/R Lead-in 28 Weeks 56% (58/103) No P/R Lead-in 48 Weeks 66% (68/103) P/R Lead-in 48 Weeks 74% (76/103) P/R Control 48 Weeks 38% (39/104) P/R Lead-in PEGINTRON and REBETOL for 4 weeks prior to the addition of boceprevir P/R Control PEGINTRON and REBETOL alone for 48 weeks SVR 12 for 48 week arms; SVR 24 for 28 week arms(2-4) In the study, predictability of attaining SVR (12 or 24) based on rapid virologic response (RVR) following 28 or 48 weeks of the boceprevir regimen was greater for patients in the lead-in arms (82 and 92 percent respectively) compared to the no lead-in arms (74 and 82 percent, respectively).
|